Annexin A2, Annexin II, Annexin-2, Calpactin I heavy chain, Calpactin-1 heavy chain, Chromobindin-8, Lipocortin II, Placental anticoagulant protein IV, PAP-IV, Protein I, p36
Annexin A2 is known by several other names including: Annexin II, Calpactin I heavy chain, Chromobindin-8, Lipocortin II and Placental anticoagulant protein IV. Annexin A2 is a calcium-regulated membrane-binding protein that binds two calcium ions with high affinity. Annexin A2′s affinity for calcium is enhanced by anionic phospholipids. Annexin A2 has been shown to bind to human cytomegalvirus (HCMV) and may be involved in heat-stress response and apoptosis.
特異性
This antibody recognizes the Annexin 1 repeat domain of Annexin A2.
免疫原
Epitope: Annexin 1 repeat domain
KLH-conjugated linear peptide corresponding to Annexin 1 repeat domain of human Annexin A2.
應用
Anti-Annexin A2 is an antibody targeting the Annexin A2 protein, validated for use in WB & IHC.
Immunohistochemistry Analysis: A 1:500 dilution from a representative lot detected Annexin A2 in human and rat colon tissues.
Research Category Apoptosis & Cancer
Research Sub Category Apoptosis - Additional
品質
Evaluated by Western Blotting in A549 cell lysate.
Western Blotting Analysis: 1.0 µg/mL of this antibody detected Annexin A2 in 10 µg of A549 cell lysate.
標靶描述
~36 kDa observed
外觀
Protein A purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
儲存和穩定性
Stable for 1 year at 2-8°C from date of receipt.
分析報告
Control A549 cell lysate
其他說明
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
An early and accurate diagnosis of ovarian carcinoma (OC) may reduce morbidity and mortality of the patients. To improve the clinical outcome in OC patients, the present study is aimed at identifying robust biomarkers for early OC diagnosis. EXPERIMENTAL DESIGN: In